Joinn Laboratories(China)Co.,Ltd. (603127.SS)
CNY 15.59
(0.65%)
CNY 15.59
(0.65%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.67 Billion CNY | -23.08% |
| 2022 | 2.17 Billion CNY | 56.06% |
| 2021 | 1.39 Billion CNY | 57.6% |
| 2020 | 883.65 Million CNY | 49.63% |
| 2019 | 590.57 Million CNY | 20.55% |
| 2018 | 489.88 Million CNY | 27.88% |
| 2017 | 383.08 Million CNY | 13.72% |
| 2016 | 336.87 Million CNY | 23.11% |
| 2015 | 273.63 Million CNY | -6.49% |
| 2014 | 292.63 Million CNY | 13.33% |
| 2013 | 258.2 Million CNY | -8.04% |
| 2012 | 280.78 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.53 Billion CNY | -12.12% |
| 2024 Q1 | 1.73 Billion CNY | 4.06% |
| 2024 Q2 | 1.74 Billion CNY | 0.37% |
| 2023 Q4 | 1.67 Billion CNY | -16.1% |
| 2023 Q1 | 2.18 Billion CNY | 0.58% |
| 2023 FY | 1.67 Billion CNY | -23.08% |
| 2023 Q3 | 1.99 Billion CNY | -9.23% |
| 2023 Q2 | 2.19 Billion CNY | 0.43% |
| 2022 Q4 | 2.17 Billion CNY | -9.76% |
| 2022 FY | 2.17 Billion CNY | 56.06% |
| 2022 Q3 | 2.4 Billion CNY | -25.69% |
| 2022 Q2 | 3.24 Billion CNY | 92.31% |
| 2022 Q1 | 1.68 Billion CNY | 21.01% |
| 2021 Q3 | 1.38 Billion CNY | 10.18% |
| 2021 Q1 | 1.03 Billion CNY | 17.43% |
| 2021 FY | 1.39 Billion CNY | 57.6% |
| 2021 Q2 | 1.25 Billion CNY | 21.41% |
| 2021 Q4 | 1.39 Billion CNY | 0.32% |
| 2020 FY | 883.65 Million CNY | 49.63% |
| 2020 Q3 | 829.53 Million CNY | 4.45% |
| 2020 Q4 | 883.65 Million CNY | 6.52% |
| 2020 Q2 | 794.18 Million CNY | 6.93% |
| 2020 Q1 | 742.67 Million CNY | 25.76% |
| 2019 Q1 | 553.42 Million CNY | 12.97% |
| 2019 FY | 590.57 Million CNY | 20.55% |
| 2019 Q4 | 590.57 Million CNY | -4.12% |
| 2019 Q3 | 615.97 Million CNY | 7.29% |
| 2019 Q2 | 574.14 Million CNY | 3.74% |
| 2018 Q4 | 489.88 Million CNY | -1.98% |
| 2018 Q2 | 449.16 Million CNY | 2.93% |
| 2018 Q1 | 436.38 Million CNY | 13.91% |
| 2018 FY | 489.88 Million CNY | 27.88% |
| 2018 Q3 | 499.78 Million CNY | 11.27% |
| 2017 Q2 | 358.63 Million CNY | 0.0% |
| 2017 Q3 | 380.3 Million CNY | 6.04% |
| 2017 FY | 383.08 Million CNY | 13.72% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q4 | 383.08 Million CNY | 0.73% |
| 2016 FY | 336.87 Million CNY | 23.11% |
| 2016 Q4 | 336.87 Million CNY | 0.0% |
| 2015 FY | 273.63 Million CNY | -6.49% |
| 2014 FY | 292.63 Million CNY | 13.33% |
| 2013 FY | 258.2 Million CNY | -8.04% |
| 2012 FY | 280.78 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 8.84 Billion CNY | 81.101% |
| WuXi AppTec Co., Ltd. | 17.66 Billion CNY | 90.539% |
| Autobio Diagnostics Co., Ltd. | 2.85 Billion CNY | 41.485% |
| Thalys Medical Technology Group Inc. | 2.02 Billion CNY | 17.535% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 3.19 Billion CNY | 47.685% |
| Chemclin Diagnostics Co., Ltd. | 431.76 Million CNY | -287.166% |